Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945444 | 0.91 | L3MBTL1 (0.63) | L3MBTL1CA1CA2MTNR1AMTNR1B | |
| SCHEMBL5945523 | 0.90 | CA1 (0.59) | L3MBTL1CA1CA2MTNR1AMTNR1B | |
| SCHEMBL5945440 | 0.90 | L3MBTL1 (0.55) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL5945532 | 0.89 | CTSD (0.51) | L3MBTL1CA1CA2LMNA | |
| SCHEMBL5146659 | 0.88 | PDK2 (0.55) | L3MBTL1CA1CA2LMNASMN1; SMN2 | |
| SCHEMBL5945490 | 0.87 | PDK2 (0.44) | L3MBTL1CA1CA2LMNA | |
| SCHEMBL5144885 | 0.87 | PDK2 (0.44) | L3MBTL1CA1CA2LMNA | |
| SCHEMBL5145141 | 0.87 | CA2 (0.46) | L3MBTL1CA1CA2LMNA | |
| Davasaicin SCHEMBL5145300 | 0.87 | L3MBTL1 (0.54) | L3MBTL1CA1CA2MTNR1AMTNR1B | |
| Davasaicin SCHEMBL30295417 | 0.87 | L3MBTL1 (0.54) | L3MBTL1CA1CA2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697303-A4 | CATALYTIC HYDROGENATION OF NITRILES TO PRODUCE CAPSAICINOID DERIVATIVES AND AMINE COMPOUNDS, AND METHODS FOR PURIFIYING AND OBTAINING THE POLYMORPHS THEREOF | STIEFEL LABORATORIES (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1697303-A1 | CATALYTIC HYDROGENATION OF NITRILES TO PRODUCE CAPSAICINOID DERIVATIVES AND AMINE COMPOUNDS, AND METHODS FOR PURIFIYING AND OBTAINING THE POLYMORPHS THEREOF | STIEFEL LABORATORIES, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060047171-A1 | Catalytic hydrogenation of nitriles to produce capsaicinoid derivatives and amine compounds, and methods for purifying and obtaining the polymorphs thereof | STIEFEL LABORATORIES, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2005068414-A1 | CATALYTIC HYDROGENATION OF NITRILES TO PRODUCE CAPSAICINOID DERIVATIVES AND AMINE COMPOUNDS, AND METHODS FOR PURIFIYING AND OBTAINING THE POLYMORPHS THEREOF | STIEFEL LABORATORIES, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-0525360-B1 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1998-03-25 | — | — | EP | disclosed |
| US-5242944-A | Analgesics or antiinflammatory agents | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-09-07 | — | — | US | disclosed |
| EP-0525360-A2 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047171-A1 | Catalytic hydrogenation of nitriles to produce capsaicinoid derivatives and amine compounds, and methods for purifying and obtaining the polymorphs thereof | HPD, HNMT, PRPH | L3MBTL1 4874/4885CA1 132/4885CA2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.